Pharmaceutical

Simtra BioPharma to invest more than $250m in US facility

Simtra BioPharma has announced plans invest $250m for an expansion of its sterile fill/finish manufacturing site in Bloomington, Indiana, US.

Mar 1, 2024 - 18:00
Simtra BioPharma to invest more than $250m in US facility
Simtra BioPharma has announced plans invest $250m for an expansion of its sterile fill/finish manufacturing site in Bloomington, Indiana, US.
Read the original article

Tags:

Previous Article

UK MHRA approves new formulation of Amgen’s XGEVA

Next Article

Rovi’s Expansion in Pharmaceutical Production with Moderna

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

Listen: Merck v. USA, the best of ASCO, and Leqembi at the FDA

Listen: Merck v. USA, the best of ASCO, and Leqembi at ...

Jun 8, 2023

STAT+: The Ozempic panic: Why a market frenzy over new weight loss drugs defies logic

STAT+: The Ozempic panic: Why a market frenzy over new ...

Oct 18, 2023

STAT+: Pharmalittle: FDA commish calls U.S. drug prices ‘too high’; FDA staff says Eisai and Biogen’s Alzheimer’s drug has benefits

STAT+: Pharmalittle: FDA commish calls U.S. drug prices...

Jun 8, 2023